NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been
filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to
request that the court appoint you as lead plaintiff.
Tenaris S.A. (NYSE: TS)
Class Period: May 1, 2014 to November 27, 2018
Lead Plaintiff Deadline: February 11, 2019
The complaint alleges that throughout the class period Tenaris S.A. made materially false and/or misleading
statements and/or failed to disclose that: (1) Tenaris’s CEO and Chairman, Paolo Rocca, knew that one of his company’s executives
paid cash to government officials from 2009 to 2012 to expedite compensation payments for the sale of Sidor; (2) this conduct would
lead to Rocca being charged in a graft scheme, and subject Tenaris, its affiliates, and/or executives to heightened governmental
scrutiny; and (3) as a result, Tenaris’s public statements were materially false and/or misleading at all relevant times. When the
true details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the TS lawsuit: http://www.kleinstocklaw.com/pslra-1/tenaris-s-a-loss-submission-form?wire=3
Teladoc Health, Inc. (NYSE: TDOC)
Class Period: March 3, 2016 to December 5, 2018
Lead Plaintiff Deadline: February 11, 2019
The complaint alleges Teladoc Health, Inc. made materially false and/or misleading statements and/or failed to
disclose that: (i) Executive Vice President and Chief Operating Officer Mark Hirschhorn was engaged in an inappropriate sexual
relationship with a subordinate; (ii) Hirschhorn and this subordinate engaged in insider trading to provide themselves with undue
benefits; (iii) Hirschhorn caused the subordinate to receive promotions for which she was unqualified, thereby negatively impacting
the Company’s operations; (iv) the Company’s enforcement of its own purported employment and trading policies were inadequate to
prevent the foregoing conduct; and (v) as a result, the Company’s public statements were materially false and misleading at all
relevant times.
Get additional information about the TDOC lawsuit: http://www.kleinstocklaw.com/pslra-1/teladoc-health-inc-loss-submission-form?wire=3
Dentsply Sirona, Inc. (NASDAQ: XRAY)
Class Period: (i) all persons who purchased the common stock of Dentsply Sirona, Inc. (NASDAQ: XRAY) between February 20, 2014 and
August 7, 2018; (ii) all Dentsply International Inc. shareholders who held shares as of the record date of December 2, 2015 and
were entitled to vote with respect to the Acquisition at the January 11, 2016 special meeting of Dentsply International Inc.
shareholders; and (iii) all persons who purchased or otherwise acquired the common stock of Dentsply International in exchange for
their shares of common stock of Sirona in connection with the Acquisition
Lead Plaintiff Deadline: February 19, 2019
According to the complaint, during the Class Period, Defendants attributed the Company’s financial performance
to the Company’s “innovation,” “operational improvement efforts,” “new products,” and “continued investments in sales and
marketing” and told investors that these factors helped the Company succeed despite the “highly competitive” market for its
products. In reality, the Company’s financial results had been buoyed by an anticompetitive scheme among the Company’s three
primary distributors that suppressed competition in the dental supply market and artificially inflated the price of dental supplies
sold by Dentsply. Further, Defendants concealed that an exclusive distribution arrangement that Sirona had with one of its
distributors, Patterson Companies, Inc. (“Patterson”), required Patterson to regularly make large minimum purchases regardless of
demand and, as a result, by 2015, Patterson had been supplied with so much excess inventory that it could not be sold. This
channel-stuffing rendered the Company’s reported sales, financial results and guidance materially false and misleading. In
addition, the Company represented that it reported its financial statements, including its goodwill, in accordance with generally
accepted accounting principles, or GAAP. In fact, the Company’s reported goodwill was artificially inflated and not reported in
accordance with GAAP because it did not reflect the financial impact of the anticompetitive scheme.
Get additional information about the XRAY lawsuit: http://www.kleinstocklaw.com/pslra-1/dentsply-sirona-inc-loss-submission-form?wire=3
AxoGen, Inc. (NASDAQ: AXGN)
Class Period: August 7, 2017 to December 18, 2018
Lead Plaintiff Deadline: March 11, 2019
Throughout the class period, AxoGen, Inc. allegedly made materially false and/or misleading statements and/or
failed to disclose that: (1) the Company aggressively increased prices to mask lower sales; (2) the Company’s pricing alienated
customers and threatened the Company’s future growth; (3) ambulatory surgery centers form a significant part of the market for the
Company’s products; (4) such centers were especially sensitive to price increases; (5) the Company was dependent on a small number
of surgeons whom the Company paid to generate sales; (6) the Company’s consignment model for inventory was reasonably likely to
lead to channel stuffing; (7) the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8)
the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) the Company lacked
adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) the Company’s key operating metrics,
such as number of active accounts, were overstated; and (11) as a result of the foregoing, Defendants’ positive statements about
the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Get additional information about the AXGN lawsuit: http://www.kleinstocklaw.com/pslra-1/axogen-inc-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or
obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J.
Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud
throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
